CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC

Rocha, Pedro; Hardy-Werbin, Max; Naranjo, Dolores; Taus, Álvaro; Rodrigo, M. T.; Zuccarino, Flavio; Roth, René P; Wood, Oliver; Ottensmeier, Christian; Arriola, Edurne

doi:10.1016/j.jtho.2018.05.008

Cited by 29 publications

(21 citation statements)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two previous reports have described that the presence of TILs was identified in the metastatic liverlesions of NSCLC patients with pseudoprogression after nivolumab treatment [1][2][3]. Rocha et al reported that pseudoprogression could be caused by an increase in tumor volume associated with the intratumoral expansion of the protective immune cells [2]. To the best of our knowledge, this is a first case report eliciting the presence of intratumoral lymphocytes within the pulmonary tissues at the maximal timing of pseudoprogression.…”

Section: To the Editormentioning

confidence: 57%

“…We found evidence of lymphocytes within the clusters of tumor cells and PD-L1 positive tumor cells in the pulmonary tumor tissue expectorated by the patient. Two previous reports have described that the presence of TILs was identified in the metastatic liverlesions of NSCLC patients with pseudoprogression after nivolumab treatment [1][2][3]. Rocha et al reported that pseudoprogression could be caused by an increase in tumor volume associated with the intratumoral expansion of the protective immune cells [2].…”

Section: To the Editormentioning

confidence: 99%

See 1 more Smart Citation

Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer

et al. 2020

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 57%

Section: To the Editormentioning

confidence: 99%

Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer

et al. 2020

View full text Add to dashboard Cite

“…Pseudoprogression is totally different from hyperprogression in terms of patient outcome. In the case of ICI therapy, pseudoprogression is defined as an initial increase of tumor size followed by a response to treatment, resulting from an exacerbated immune cell infiltration in the tumor bed, including CD103+ CD8+ cells (42). Pseudoprogression remains a rare response pattern as its average occurrence rate is only 10% in melanoma (11,41,(43)(44)(45).…”

Section: Pseudoprogressionmentioning

confidence: 99%

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?

et al. 2020

View full text Add to dashboard Cite

Following the administration of immune checkpoint inhibitors, an unexpected pattern of response designated as hyperprogression may be observed in certain patients. This paradoxical response corresponds to an acceleration in tumor growth and a dramatic decrease of patient survival. The reported incidence rates of hyperprogressive disease are highly variable, ranging between 4 and 29%. In this review, we have performed a literature search on hyperprogressive disease, including both retrospective studies and case reports, and discuss potential predictive biomarkers as well as potential mechanisms associated with immune-checkpoint inhibitor associated hyperprogression.

show abstract

“…25 Tumor biopsy at progression may further assist by identification of tumoral immune cell infiltration in cases with pseudoprogression. 26 These specific imaging manifestations in patients receiving immunotherapy necessitate supplanting the classical criteria with a tailored radiologic imaging assessment.…”

Section: Pseudoprogressionmentioning

confidence: 99%

Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies

Uhlig

Biggemann

Sheth

et al. 2020

Digestive Disease Interventions

View full text Add to dashboard Cite

In recent years, systemic cancer treatment has been revolutionized with the advent of immunotherapy, which utilizes the body's immune system to target cancer cells and results in unique and novel imaging patterns of cancer response and therapy-associated toxicities. Hyperprogression is defined as a rapid tumor progression after treatment initiation. In contrast, pseudoprogression is defined as a tumor response after an initial increase in tumor burden, or appearance of new tumor lesions, and observed in <10% of patients undergoing PD-1/PD-L1 immunotherapy. Since traditional radiological strategies might not fully capture tumor response of patients receiving immunotherapy, several efforts have been made to better quantify specific immuno-oncological imaging patterns, including immune-related response criteria, immune-related RECIST, immunotherapy RECIST, and modified RECIST. These criteria account for potential pseudoprogression, and thus may prevent preemptive immunotherapy cessation. Immunotherapy is also associated with specific immune-related adverse events, including colitis (8–22% of patients), hypophysitis (8–13%), pneumonitis (<4%), lymphadenopathy (5–7%), hepatitis (1–7%), and pancreatitis (2%). Quantification of imaging studies using radiomic features has shown promising results in immuno-oncology, including prediction of individual patient's treatment response and survival, as well as characterization of tumoral expression of immunotherapy-relevant targets.

show abstract

CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC

Cited by 29 publications

References 5 publications

Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer

Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?

Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies

Contact Info

Product

Resources

About